
Pfizer Reports Positive Phase 2 Topline Results for Atirmociclib, a Next-Generation CDK4 Inhibitor, in Second-Line Metastatic Breast Cancer
Pfizer reports positive Phase 2 topline results for next-generation CDK4 inhibitor atirmociclib in second-line metastatic breast cancer Pfizer Inc. today announced positive topline results from the randomized Phase 2 FOURLIGHT-1…











